Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Frontiers in Medicine
Main Authors: Thomas Mika, Katharina Strate, Swetlana Ladigan, Clemens Aigner, Uwe Schlegel, Iris Tischoff, Sabine Tischer-Zimmermann, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Roland Schroers
Formato: Artigo
Publicado em: Frontiers Media S.A. 2019-12-01
Assuntos:
PTLD
AlloHSCT
Aggressive lymphoma
Brentuximab vedotin (BV)
Third-party EBV-specific T-lymphocytes
Acesso em linha:https://www.frontiersin.org/article/10.3389/fmed.2019.00295/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://www.frontiersin.org/article/10.3389/fmed.2019.00295/full

Registos relacionados